The most recent guidelines for managing uveitis advocate for a stepwise approach, commencing with the use of topical, periocular, and systemic corticosteroids (CS), progressing to immunomodulatory therapy (IMT), and ultimately considering the adoption of biologic therapy, preferably a TNF-α inhibitor. This evidence concerns the gene TNF and uveitis.